Cointime

Puma Biotechnology

company

About

Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.

  • 251 - 500

Highlights

Total Funding Amount
$55M
Funding Rounds
1
Investors
1
Investments
1

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$55M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2010
Number Of Employee
251 - 500
Operating Status
Active

Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$55M
Puma Biotechnology has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Oct 5, 2011 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 5, 2011 Post-IPO Equity $55M 1 — — Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Puma Biotechnology has made 1 investments. Their most recent investment was on Mar 30, 2017, when Ledger raised $7M.
Date Company Name
Round Money Raised Industry Lead Investor
Mar 30, 2017 Ledger
Series A $7M Cryptocurrency —

Investors

Number of Lead Investors
Number of Investors
—
1
Puma Biotechnology is funded by 1 investors. H&Q Healthcare Investors are the most recent investors.
Investor Name Lead Investor Funding Round
H&Q Healthcare Investors — Post-IPO Equity
Cointime
Content
Company